Cargando…

Chemoproteomic target deconvolution reveals Histone Deacetylases as targets of (R)-lipoic acid

Lipoic acid is an essential enzyme cofactor in central metabolic pathways. Due to its claimed antioxidant properties, racemic (R/S)-lipoic acid is used as a food supplement but is also investigated as a pharmaceutical in over 180 clinical trials covering a broad range of diseases. Moreover, (R/S)-li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lechner, Severin, Steimbach, Raphael R., Wang, Longlong, Deline, Marshall L., Chang, Yun-Chien, Fromme, Tobias, Klingenspor, Martin, Matthias, Patrick, Miller, Aubry K., Médard, Guillaume, Kuster, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272112/ https://www.ncbi.nlm.nih.gov/pubmed/37322067 http://dx.doi.org/10.1038/s41467-023-39151-8

Ejemplares similares

Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target
por: Lechner, Severin, et al.
Publicado: (2022)

High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells
por: Krumm, Johannes, et al.
Publicado: (2023)

Dissection of Targeting Molecular Mechanisms of Aristolochic Acid-induced Nephrotoxicity via a Combined Deconvolution Strategy of Chemoproteomics and Metabolomics
por: Zhang, Qian, et al.
Publicado: (2022)

Histone deacetylase-10 liberates spermidine to support polyamine homeostasis and tumor cell growth
por: Stewart, Tracy Murray, et al.
Publicado: (2022)

Chemoproteomic profiling reveals cellular targets of nitro-fatty acids
por: Fang, Ming-Yu, et al.
Publicado: (2021)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics
por: Ghidelli-Disse, Sonja, et al.
Publicado: (2014)

A chemoproteomic platform to quantitatively map targets of lipid-derived electrophiles
por: Wang, Chu, et al.
Publicado: (2013)

A chemoproteomic method for identifying cellular targets of covalent kinase inhibitors
por: Chen, Ying-Chu, et al.
Publicado: (2016)

Chemoproteomic profiling of targets of lipid-derived electrophiles by bioorthogonal aminooxy probe
por: Chen, Ying, et al.
Publicado: (2017)

A Paal–Knorr agent for chemoproteomic profiling of targets of isoketals in cells
por: Wang, Min-Ran, et al.
Publicado: (2021)

Targeting Huntington’s disease through histone deacetylases
por: Gray, Steven G.
Publicado: (2011)

DNA and histone deacetylases as targets for neuroblastoma treatment
por: Stiborová, Marie, et al.
Publicado: (2010)

Targeting histone deacetylases in pancreatic ductal adenocarcinoma
por: Schneider, Günter, et al.
Publicado: (2010)

Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer
por: Beljkas, Milan, et al.
Publicado: (2023)

Chemoproteomic profiling of itaconations in Salmonella
por: Zhang, Yanling, et al.
Publicado: (2021)

Crystal Structure of Histone Deacetylase 6 Complexed with (R)-Lipoic Acid, an Essential Cofactor in Central Carbon Metabolism
por: Watson, Paris R., et al.
Publicado: (2023)

Crystal structure of histone deacetylase 6 complexed with (R)-lipoic acid, an essential cofactor in central carbon metabolism
por: Watson, Paris R., et al.
Publicado: (2023)

Targeted inhibition of histone deacetylase 6 in inflammatory diseases
por: Ran, Jie, et al.
Publicado: (2019)

Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
por: Ruzic, Dusan, et al.
Publicado: (2022)

Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression
por: Park, Hyun-Sun, et al.
Publicado: (2021)

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
por: Li, Yan, et al.
Publicado: (2022)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
por: Badie, Amandine, et al.
Publicado: (2022)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

Targeting histone deacetylases for cancer therapy: Trends and challenges
por: Liang, Tao, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

A chemoproteomic portrait of the oncometabolite fumarate
por: Kulkarni, Rhushikesh A., et al.
Publicado: (2019)

Histone deacetylases – a new target for suppression of cartilage degradation?
por: Mort, John S
Publicado: (2005)

Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions
por: Hoeksema, Marten A, et al.
Publicado: (2014)

Targeting Histone Deacetylases: A Novel Approach in Parkinson's Disease
por: Sharma, Sorabh, et al.
Publicado: (2015)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
por: Okabe, Seiichi, et al.
Publicado: (2021)

Histone deacetylase 10, a potential epigenetic target for therapy
por: Cheng, Fajuan, et al.
Publicado: (2021)

Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
por: Sim, Wynne, et al.
Publicado: (2022)

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis
por: Jiang, Li-Ping, et al.
Publicado: (2022)

Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma
por: Yang, Qiwei, et al.
Publicado: (2022)

Photocaged Histone Deacetylase Inhibitors as Prodrugs in Targeted Cancer Therapy
por: Kraft, Fabian B., et al.
Publicado: (2023)

Medicinal chemistry advances in targeting class I histone deacetylases
por: Abdallah, Diaaeldin I., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_efd2lmusdhehr0mi65f2jg7ihs